Evolva Holding LTD
EVE
ISIN CH1262055788 / Valor 126205578
Evolva Holding LTD
UMushroom community rating:
About company
Evolva Holding Ltd is a Swiss biotechnology company that develops and commercializes ingredients for food, nutrition, health and consumer-product markets by applying synthetic biology and precision fermentation to produce specialty molecules that are difficult, costly or unsustainable to obtain from traditional sources. The company combines discovery and strain‑engineering with process development and scale‑up, then brings products to market through manufacturing partnerships, supply agreements and licensing to ingredient and brand customers. Its commercial focus is on high‑value, low‑volume compounds such as flavor and fragrance molecules and nutritional or bioactive ingredients, together with related contract manufacturing and regulatory pathways needed to support customer adoption.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (02.05.2026):
Evolva Holding LTD — half‑year / Q2 2025 (period from 1 January to 30 June 2025): The company (now renamed EvoNext Holdings Ltd) reported no revenue and a net loss for the half‑year of CHF 361.2k, driven by ongoing corporate costs after the sale of its operating subsidiary; cash at period end was CHF 6.313m and total equity stood at CHF 6.235m.
Result
Net loss of CHF 361.2k for the period 1 Jan–30 Jun 2025 (vs. a net profit of CHF 1,533.5k in 1H 2024). Operating loss was CHF 367.3k.
Revenue and operations
No revenue, cost of goods sold or R&D expenses in 1H 2025 following the sale of Evolva AG on 28 Dec 2023; the Company has no active operating business.
Expenses
Commercial, general & administrative expenses of CHF 367.3k in 1H 2025. The 1H 2024 comparative included a reversal of liquidation accruals, which made 2024 look positive.
Cash flow and liquidity
Cash and cash equivalents decreased by CHF 440.3k in the half‑year to CHF 6.313m at 30 June 2025. Operating cash outflow for the period was CHF 440.3k; no financing inflows were recorded in 1H 2025.
Balance sheet and equity
Total assets CHF 7.085m and total equity CHF 6.235m at 30 June 2025. Issued share capital unchanged (7,230,626 shares, share capital CHF 7,230.6k).
Provisions, earn‑out and contingencies
Provision of CHF 600.0k remains for a potential price adjustment related to the sale of Evolva AG. The earn‑out from Danstar Ferment AG for Jan–Jun 2025 did not meet the sales floor, so no earn‑out payment is expected for 1H 2025. The company prevailed in an arbitration and was awarded approx. CHF 88k (accrued and received in July 2025).
Corporate and going concern
The company has no employees as of 30 June 2025. Shareholders approved changing the name to EvoNext Holdings Ltd in July 2025. Management notes a material uncertainty over going concern beyond 2025 if no strategic transaction (e.g., reverse takeover) or buyer is found.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
12 M
Market cap (USD)
16,370
Daily traded volume (Shares)
0.896 / 0.8
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
D Y
Roger Schaad
EQUITIES OF THE SAME SECTOR
